Ron Branning Joins Genzyme to Lead Global Product Quality
Genzyme Corporation announced that Ron Branning, a 30-plus year bio/pharmaceutical veteran specializing in the development of world-class drug and device quality monitoring systems and regulatory compliance management practices, has joined the company as Senior Vice President of Global Product Quality. In this role, he will ensure the quality of all Genzyme products manufactured at seventeen sites around the world.
Prior to joining Genzyme, Mr. Branning led the quality and compliance functions at Gilead Sciences, where he was Corporate Vice President of Quality and Compliance, and Chief Compliance Officer. He has also held senior quality leadership positions at Genentech, Aventis Behring, and Somatogen (Baxter). Earlier in his career, he developed extensive quality experience at Genetics Institute (Wyeth), Boehringer Ingelheim, GD Searle (Pfizer) and Johnson & Johnson.
Mr. Branning has had oversight responsibility for a diverse range of products, including biologics, small molecules, and devices. His experience also includes the development of organizational models and systems that produce measureable and successful quality and compliance practices across multiple manufacturing sites. During his career, he has been recruited to build quality programs and compliance systems that resolved significant challenges, including FDA warning letters, consent decrees, product recalls, and FDA 483 post-inspection letters.
Mr. Branning will report to Genzyme executive vice president David Meeker, M.D., and have a direct reporting line to CEO Henri Termeer.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
